Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
From - Diagnostic Testing & Emerging Technologies
There is universal recognition that genomic information has forever changed oncology care and is increasingly driving treatment decisions. For patients who have exhausted standard therapy or with…
From - Diagnostic Testing & Emerging Technologies
More than 28 percent of the novel new drugs approved by U.S. Food and Drug Administration (FDA) in 2015 were…
From - Diagnostic Testing & Emerging Technologies
Prostate specific antigen (PSA) testing varies significantly by physician specialty, according to a research letter published online Feb. 8 in…
From - Diagnostic Testing & Emerging Technologies
Simple, brief, information sheets are unlikely to change patients' intentions to participate in low-value screenings, according to a study published online…